Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of October 2013. The report details a capital raising event completed on October 23, 2013, pursuant to a shelf registration report in Israel.
Key Financial Metrics
The filing focuses on the proceeds from a private placement rather than operational financial results.
- Units Sold: 3,675 units.
- Securities Issued: 1,837,500 Ordinary Shares and 1,378,125 Series 12 Options.
- Price Per Unit: NIS 5,800 (approximately $1,648.52 USD).
- Gross Proceeds: NIS 21,315,000 (approximately $6,058,323.62 USD).
- Net Proceeds: NIS 20,226,250 (approximately $5,748,870.19 USD) after sales commissions.
- Exchange Rate Used: NIS 3.51830 to $1.00 USD.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of 1,837,500 new ordinary shares and associated options. The filing does not provide comparative data to prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the capital raise. The transaction was executed under a shelf registration in Israel.
Investor Verification Checklist
- Verify the current share count and the percentage dilution resulting from the issuance of 1,837,500 new shares.
- Confirm the terms and exercise price of the 1,378,125 Series 12 Options issued.
- Review the attached press release (Exhibit 99.1) for the intended use of the approximately $5.75 million in net proceeds.
- Check subsequent filings for the impact of this capital raise on the company's liquidity and runway.